Oncoinvent ASA: Notice of Annual General Meeting

Oslo, Norway, 28 April 2026 - Oncoinvent ASA (ONCIN), will be holding its Annual General Meeting virtual on 20 May 2026 at 10:00 hours (CEST).

The notice and agenda of the annual general meeting is attached hereto, including further information on advance voting, power of attorney and physical participation. The notice will be sent to all registered shareholders, and the notice, the compensation report, the nomination committees recommendations and other documents referred to therein are made available on the Company's website: https://www.oncoinvent.com/investors/general-meetings/.

Oncoinvent ASA - Notice to AGM 2026.pdf (https://mb.cision.com/Public/15728/4341307/91b5ce77dcea1d84.pdf)

All shareholders are encouraged to exercise their shareholder rights, either through advance electronically voting through VPS Investor Services, by using the enclosed proxy form to provide proxy to the Chairman Gillies O'Bryan-Tear (or the person he appoints), or to attend the general meeting virtually.

Registration, advance vote or proxy for the Annual General Meeting can be registered through the company's website (https://www.oncoinvent.com/investors/general-meetings/) or VPS Investor Service (https://investor.vps.no/garm/auth/login) within 18 May 2026, 23:59 hours (CEST). Virtual participants also need to be logged in to the meeting before 10:00 hours (CEST) 20 May 2026. All shareholders will receive a reference number and a pin code required for registration through the company's website. Reference number and pin code will be received either by VPS Investor Service or by post depending on if the shareholder is registered as electronical user. We encourage all shareholders to register as electronical users in VPS.

For further information, please contact:

Oystein Soug, Chief Executive Officer Email: IR@oncoinvent.com (soug@oncoinvent.com)

This information is subject to the disclosure requirements pursuant to Euronext Oslo Rule Book II for companies listed on Oslo Børs and Section 5-12 of the Norwegian Securities Trading Act.

About Oncoinvent

Oncoinvent is developing Radspherin[®], a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs.

This radiopharmaceutical is designed to prevent or delay recurrence in the peritoneal cavity, keeping patients disease-free for longer than the current standard of care and thereby also impacting overall survival. It is broadly applicable to any cancer that spreads to the peritoneum, e.g. ovarian, colorectal, and gastric cancers. Radspherin[®] stands out for its simplicity, excellent safety profile, and seamless integration into existing surgical workflows. Oncoinvent's product is easy to use, avoids systemic delivery and significant toxicity. It is also differentiated in being simple to manufacture, scalable, and supply de-risked.

Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers, are highly promising, showing an excellent safety profile and meaningful signals of efficacy. Interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in 2026. With cost-effective manufacturing, blockbuster potential, active pharma partnership momentum, plus strong endorsements from leading experts, Oncoinvent is built for scale and commercial success, and is set to become the new standard for post-surgical cancer care. The Company was founded by the originators of Algeta and Xofigo (acquired by Bayer).